Form 4 Atrium Therapeutics Inc For: 27 September By Investing.com
This article reports on the Form 4 filing for Atrium Therapeutics Inc. on September 27. It is a brief financial news item from Investing.com, providing basic information about the regulatory filing.
Form 4 Atrium Therapeutics Inc For: 27 September By Investing.com
The article reports on a Form 4 filing for Atrium Therapeutics Inc. on September 27. It also includes a stock market snapshot, commodity prices, bond yields, and trending stock information, but provides no further details on the Form 4 itself.
Atrium Therapeutics stock advances its RNA pipeline toward Phase I/ II
Atrium Therapeutics is advancing its RNA therapeutics pipeline, particularly its lead PRKAG2 program, towards a Phase I/II study with initial data expected in the second half of 2027. The company closed at USD 9.22 on Nasdaq and reported USD 30 million in milestone payments from a collaboration with Bristol Myers Squibb, which provides non-dilutive capital to fund operations through mid-2028. This funding supports the company's early clinical timetable as it moves from regulatory preparation to patient dosing.
RNA: Atrium Therapeutics Inc. Latest Stock Price, Analysis, News and Trading Ideas
Atrium Therapeutics Inc. (RNA) is a biopharmaceutical company focused on developing RNA therapeutics for cardiomyopathies, with lead candidates ATR 1072 and ATR 1086 addressing severe, life-threatening conditions. The company's stock is currently trading at $8.55 with a market capitalization of $141.81M, and it was founded on September 30, 2025. Recent news includes inducement grants under Nasdaq Listing Rule 5635(c)(4) and participation in upcoming investor conferences.
Tax withholding trims Atrium Therapeutics (RNA) director's stake
Atrium Therapeutics (RNA) director Sarah Boyce had 126,418 shares of common stock withheld on September 18, 2026, to cover tax obligations from restricted stock unit vesting. After this transaction, she directly holds 138,668 shares. The filing indicates this was a tax withholding, not a market sale, and no Rule 10b5-1 trading plan was involved.
2,375 Atrium Therapeutics (RNA) shares withheld for taxes
Atrium Therapeutics' Chief Corporate Affairs Officer, Stephanie Kenney, had 2,375 shares of common stock withheld on September 18, 2026, to cover tax withholding obligations related to the vesting of restricted stock units. This disposition resulted in Kenney directly holding 33,085 shares of common stock, and the transaction was not made under a Rule 10b5-1 plan. The shares were valued at $8.95 each for tax purposes.
Director at Atrium Therapeutics (RNA) has 22,812 shares withheld for taxes
Atrium Therapeutics director Michael W. Flanagan reported a Form 4 reflecting the withholding of 22,812 shares of Common Stock on September 18, 2026. This action was taken to satisfy tax withholding obligations arising from the vesting of restricted stock units, and not as an open-market trade. Following this transaction, Flanagan directly holds 31,974 shares of Common Stock.
Form 4 Atrium Therapeutics Inc For: 22 September By Investing.com
This article announces the filing of a Form 4 for Atrium Therapeutics Inc. on September 22. It is a brief financial news update published by Investing.com. The content provided is minimal, primarily indicating the occurrence of the SEC filing.
Form 4 Atrium Therapeutics Inc For: 22 September By Investing.com
This article reports on a Form 4 filing for Atrium Therapeutics Inc., dated September 22. Form 4 is a document required by the SEC when there is a change in beneficial ownership of securities by a company's officers, directors, or 10% shareholders. The brief piece indicates that this financial disclosure is available through Investing.com.
One new hire gets 13,500 options and 6,750 stock units from Atrium Therapeutics
Atrium Therapeutics (RNA) granted equity inducement awards to a newly hired non-executive employee on September 20, 2026, under its 2026 Employment Inducement Incentive Award Plan. The employee received non-qualified stock options for 13,500 shares at an exercise price of $8.95 per share and restricted stock units for 6,750 shares, both with specific vesting schedules. These awards were approved by the Human Capital Management Committee of the board, in accordance with Nasdaq Listing Rule 5635(c)(4).
21K Atrium Therapeutics (RNA) shares withheld for CMO's taxes
Atrium Therapeutics' Chief Medical Officer, Steven George Hughes, had 21,459 shares withheld for tax obligations related to restricted stock unit vesting. This transaction, valued at $8.95 per share, reduced his direct holdings to 51,638 shares. The event was documented in a Form 4 SEC filing on September 22, 2026.
Tax withholding trims 11,632 Atrium Therapeutics (RNA) shares, not a market sale
Atrium Therapeutics (RNA) CEO, Kathleen P. Gallagher, had 11,632 shares of common stock withheld on September 18, 2026, to cover tax obligations related to vesting restricted stock units. This was not a market sale, and she continues to hold 119,729 shares. The withheld shares were valued at $8.95 each.
Atrium Therapeutics CMO Steven George Hughes Reports Tax-Related Share Withholding on RSU Vesting
Steven George Hughes, CMO of Atrium Therapeutics, Inc., reported a tax-related share withholding on RSU vesting. On September 18, 2026, 21,459 common stock shares were withheld at $8.95 each to satisfy tax obligations from the vesting of restricted stock units. After this transaction, Hughes retains direct ownership of 51,638 common stock shares.
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Atrium Therapeutics, Inc. (Nasdaq: RNA) announced inducement grants made on September 20, 2026, under its 2026 Employment Inducement Incentive Award Plan. These grants were given to a newly hired non-executive individual and included non-qualified stock options for 13,500 shares and restricted stock units for 6,750 shares, both vesting over time. The awards were approved by the Human Capital Management Committee of the Company's Board of Directors in compliance with Nasdaq Listing Rule 5635(c)(4).
Atrium Therapeutics, Inc. - Common Stock (Nasdaq:RNA) Price Chart
This article provides the current stock price and chart information for Atrium Therapeutics, Inc. (Nasdaq: RNA). As of September 24, 2026, at 3:16 PM EDT, the stock was trading at 8.260, down 0.070 (-0.84%). The page also offers various financial tools and data from FinancialContent.
Atrium Therapeutics, Inc. (RNA) Stock Analysis: Riding the Wave of a 141% Potential Upside
Atrium Therapeutics, Inc. (RNA) shows a substantial potential upside of 141.31% according to analyst consensus. This biopharmaceutical company focuses on RNA therapeutics for cardiomyopathies, backed by collaborations with industry leaders like Bristol-Myers Squibb and Eli Lilly. Despite being a development-stage firm with current revenue declines, analysts maintain a "buy" rating with a $25.00 price target, highlighting its speculative yet promising growth prospects in the biotech sector.
Atrium Therapeutics to Participate in Upcoming Investor Conferences
Atrium Therapeutics, Inc. announced its participation in several upcoming investor conferences in September, including the Wells Fargo 21st Annual Healthcare Conference, the 2026 Cantor Global Healthcare Conference, and the Morgan Stanley 24th Annual Global Healthcare Conference. The company, a biopharmaceutical firm developing RNA therapeutics for heart conditions, highlighted recent progress such as FDA clearance for ATR-1072 for PRKAG2 syndrome and the launch of its Corventis™ Phase 1/2 clinical trial. Details for webcasts of these events will be available on Atrium's investor relations website.
Atrium Therapeutics to Participate in Upcoming Investor Conferences
Atrium Therapeutics, a biopharmaceutical company specializing in RNA therapeutics for cardiology, announced its participation in several upcoming investor conferences in September 2026. These conferences include the Wells Fargo 21st Annual Healthcare Conference, the 2026 Cantor Global Healthcare Conference, and the Morgan Stanley 24th Annual Global Healthcare Conference. The company will discuss its recent progress, including FDA clearance for ATR-1072, the launch of its Corventis™ Phase 1/2 clinical trial, and its proprietary RNA delivery platform designed for heart-targeted therapies.
A new Atrium hire gets options on 11,000 shares and 5,500 restricted units
Atrium Therapeutics (Nasdaq: RNA) granted equity inducement awards to a new non-executive employee on August 20, 2026. The awards include non-qualified options for 11,000 shares at an exercise price of $13.48 and 5,500 restricted stock units, both with multi-year time-based vesting schedules. These grants were approved by the board's independent Human Capital Management Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Atrium Therapeutics (RNA): RA Capital and affiliates report 0% beneficial ownership
RA Capital Management, L.P., and its affiliates, including Peter Kolchinsky and Rajeev Shah, have filed an amended Schedule 13G/A, reporting 0% beneficial ownership of Atrium Therapeutics (RNA) common stock as of June 30, 2026. This indicates they hold no shares and possess no voting or dispositive power over Atrium Therapeutics stock, falling below the 5% ownership threshold. The filing confirms that each reporting person now owns 5 percent or less of the common stock.
Form 8K Atrium Therapeutics Inc For: 13 August By Investing.com
This article reports on the filing of a Form 8K by Atrium Therapeutics Inc. for August 13. The brief notice highlights this corporate action as reported by Investing.com, a financial markets news service. No further details about the content of the Form 8K are provided within the article.
Sessa Capital discloses 8.8% Atrium Therapeutics (RNA) ownership through managed funds
Sessa Capital IM, L.P. and John Petry have reported a beneficial ownership of 1,500,000 shares of Atrium Therapeutics, Inc. common stock, which accounts for 8.8% of the outstanding shares. This disclosure was made via a SCHEDULE 13G SEC filing, indicating a passive investment. The shares are held by Sessa funds managed by Sessa Capital IM, L.P., with Sessa Capital (Master), L.P. having rights to dividends or sale proceeds from over 5% of the common stock.
T. Rowe Price Associates (RNA) discloses 8.6% Atrium Therapeutics ownership in 13G/A
T. Rowe Price Associates, Inc. has filed an amended Schedule 13G, disclosing a beneficial ownership of 1,472,984 shares in Atrium Therapeutics Inc., which constitutes an 8.6% stake in the company. The filing indicates that T. Rowe Price Associates holds sole voting power over 1,472,772 shares and sole dispositive power over all 1,472,984 shares, with no shared voting or dispositive powers. Despite the disclosure, the firm explicitly denies beneficial ownership of these securities.
Atrium Therapeutics, Inc. (RNA) Stock Price, News, Quote & History
Atrium Therapeutics, Inc. (RNA), formerly Prosensa Holding B.V. Ordinary Shares, is a biopharmaceutical company focused on developing RNA therapeutics for cardiomyopathies. The company's stock is currently trading at $12.84, with a slight increase after hours. Analysts maintain a "Buy" rating with a target price of $25.00, despite the company showing negative earnings per share and a negative profit margin.
Form 8K Atrium Therapeutics Inc For: 13 August By Investing.com
Investing.com reports that Atrium Therapeutics Inc. filed a Form 8K on August 13th. The brief article mentions the filing of this corporate document. No further details about the content of the Form 8K are provided.
Atrium Therapeutics, Inc. Q2 2026: Revenue $3M, EPS $(1.18) — 10-Q Summary
Atrium Therapeutics, Inc. reported its Q2 2026 results, with revenue declining to $3M from $3.85M in the prior year, and a diluted loss per share of $(1.18), worse than $(0.75) year-over-year. Despite the financial decline, the company highlighted an increase in collaboration revenue, clinical progress with FDA clearance for ATR 1072, and the successful spin-off from Avidity. R&D and G&A expenses increased to support planned clinical launches and public-company operations.
Form 8K Atrium Therapeutics Inc For: 13 August By Investing.com
This article from Investing.com is a brief announcement regarding an 8K filing by Atrium Therapeutics Inc. for August 13th. The content is very minimal, essentially serving as a headline to notify readers of the regulatory filing, without providing any further details about the filing itself.
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
Atrium Therapeutics has received a $15 million milestone payment from Bristol Myers Squibb for successfully delivering a lead compound targeting a cardiology indication. This payment is part of their global collaboration to develop RNA-based therapies for cardiovascular diseases, with Atrium eligible for up to $1.35 billion in R&D milestones and $825 million in commercial milestones, plus royalties. The collaboration leverages Atrium's RNA delivery platform, designed to selectively target the underlying causes of genetically driven cardiac diseases.
Atrium Therapeutics Reports Second Quarter 2026 Financial Results
Atrium Therapeutics reported its Q2 2026 financial results, highlighting the FDA clearance of its IND application for ATR 1072 and the launch of the Corventis Phase 1/2 trial for PRKAG2 syndrome. The company also announced a $15 million milestone payment from Bristol Myers Squibb and provided financial figures for the quarter, including $3.0 million in collaboration revenue and $263.9 million in cash and short-term investments. Atrium expects its current cash to fund operations through mid-2028.
Atrium Therapeutics Reports Second Quarter 2026 Financial Results
Atrium Therapeutics announced its second quarter 2026 financial results, highlighting FDA clearance for its ATR 1072 IND application and the launch of the Corventis Phase 1/2 trial for PRKAG2 syndrome. The company also received a $15 million milestone payment from Bristol Myers Squibb under their cardiovascular collaboration. Atrium's financial position includes $263.9 million in cash and equivalents, projected to fund operations through mid-2028.
Atrium Therapeutics (Nasdaq:RNA) - Stock Analysis
This Simply Wall Street analysis provides an overview of Atrium Therapeutics (Nasdaq:RNA), a biopharmaceutical company focused on RNA therapeutics for cardiomyopathies. The report highlights the company's recent FDA clearance for its investigational new drug ATR 1072 for PRKAG2 syndrome, its Q1 2026 earnings exceeding analyst expectations, and identifies key risks such as forecasted declining earnings and current unprofitability. It also details the company's financial health, recent announcements, and market performance.
Atrium Therapeutics, Inc. (RNA) Stock Analysis: Exploring a Potential 102.59% Upside in the Booming RNA Therapeutics Market
Atrium Therapeutics, Inc. (RNA) is a biotechnology company focused on RNA therapeutics for cardiomyopathies, attracting investor attention despite its current stock price near its 52-week low. Analysts project a potential upside of 102.59%, with an average target price of $25.00, supported by a strong buy consensus. The company, which has a market cap of $211.08 million, is in a developmental stage with a high revenue growth of 1,148.30% and strategic collaborations with pharmaceutical giants.
H.C. Wainwright Initiates Atrium Therapeutics(RNA.US) With Buy Rating, Announces Target Price $25
H.C. Wainwright has initiated coverage on Atrium Therapeutics (RNA.US) with a Buy rating. The firm has set a target price of $25 for the company's stock. This new coverage and price target suggest a positive outlook from H.C. Wainwright on Atrium Therapeutics' future performance.
Enterprise value to EBITDA forward of Atrium Therapeutics, Inc. – NASDAQ:RNA
This article from TradingView presents financial data for Atrium Therapeutics, Inc. (NASDAQ:RNA), specifically focusing on its enterprise value to EBITDA forward. It indicates that the market for RNA was closed with no trades at the time of publication. The content appears to be an excerpt from a financial data platform, providing a snapshot of a specific financial metric for the company.
Atrium Therapeutics, Inc. Revenue Breakdown – NASDAQ:RNA
Atrium Therapeutics, Inc. (NASDAQ: RNA) generated $18.60 million USD in revenue last year, primarily from its Ribonucleic Acid Therapeutics segment, which contributed $18.62 million USD. The majority of this revenue, $18.62 million USD, came from the United States. This represents an increase from the previous year's total revenue of $10.90 million USD.
Avidity Biosciences Inc (RNA) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Avidity Biosciences Inc (RNA), detailing its volatility, financial risk, and investment risk. It highlights the company's current risk score of 4.87, ranking 79 out of 155 in the Pharmaceuticals industry, and discusses its beta value of 0.00, indicating a tendency to underperform in up-trending markets but experience smaller declines in down-trending markets. Key metrics such as maximum drawdown, volatility, Sharpe ratio, and liquidity are presented over various timeframes.
Avidity Biosciences Inc (RNA) Financial Health: Profitability & Balance Sheet Analysis
Avidity Biosciences Inc (RNA) has a robust financial score of 9.13, ranking 13th in the Pharmaceuticals industry. The company reported a significant year-over-year revenue increase of 1148.25% to $19.64M and an 85.63% increase in net profit. However, specific data for Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns have not been disclosed by the company.
Avidity Biosciences Inc (RNA) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Avidity Biosciences Inc (RNA), detailing its price momentum score of 3.55 and market performance. It outlines key support and resistance levels, and presents a comprehensive overview of various technical indicators, including MACD, RSI, and moving averages, along with their current signals. The analysis also includes an FAQ section to clarify common concepts like technical ratings and moving averages, concluding with a neutral signal based on current indicators and moving averages.
BlackRock (RNA holder) discloses 6.6% Atrium Therapeutics stake in amended ownership filing
BlackRock, Inc. has filed an amended ownership report (SCHEDULE 13G/A) disclosing a 6.6% beneficial ownership stake in Atrium Therapeutics, Inc. This represents 1,135,757 shares of common stock, with BlackRock holding sole voting power over 1,119,668 shares and sole dispositive power over all beneficially owned shares. The filing indicates that no single client of BlackRock holds more than five percent of Atrium Therapeutics' outstanding common shares.
Avidity Biosciences Inc (RNA) Income Statement
This article provides the quarterly and annual income statement data for Avidity Biosciences Inc (RNA), detailing its financial performance including total revenue, operating expenses, net income, and earnings per share. It covers financial figures from FY2019Q1 up to FY2026Q1, allowing for an in-depth analysis of the company's financial trends over time. The document also includes an FAQ section explaining how to interpret income statements and key financial metrics for RNA stock.
Avidity Biosciences Inc (RNA) Cash Flow
This article provides a detailed historical cash flow statement for Avidity Biosciences Inc (RNA), covering quarterly data for operating, investing, and financing activities. It also includes an overview of key cash flow metrics and changes year-over-year, as well as FAQs explaining what operating, investing, financing, and free cash flows represent. The data presented aims to help evaluate the company's financial soundness and stability.
Stock Score & Comprehensive Stock Analysis of Avidity Biosciences Inc (RNA) - Tradingkey
This article provides a comprehensive stock analysis of Avidity Biosciences Inc (RNA) from TradingKey, highlighting its robust fundamentals, high growth potential, and fair valuation within the Pharmaceuticals industry. The analysis details the company's innovative RNA therapeutics, its strong financial performance, high institutional ownership, and mixed short-to-medium term price predictions from analysts. It also outlines TradingKey's methodology for generating stock scores across various dimensions, including financial health, valuation, earnings forecasts, price momentum, institutional confidence, and risk assessment.
Avidity Biosciences Inc (RNA) Institutional Confidence
Avidity Biosciences Inc (RNA) has an institutional shareholding score of 3.00, placing it 92nd out of 155 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 29.04%, marking a significant quarter-over-quarter decrease of 70.62%. Paul Tudor Jones is the largest institutional shareholder, holding 73.39K shares, which represents 0.42% of shares outstanding.
Avidity Biosciences Inc (RNA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Avidity Biosciences Inc (RNA), detailing its financials by region. While segment and detailed regional data are not yet disclosed by the company, the article notes a United States revenue contribution of $18.62 million. It includes current stock performance and market capitalization details.
RNA|Avidity Biosciences Inc|Price:11.635|Chg%:+0.145
Avidity Biosciences Inc is a biopharmaceutical company focused on developing a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The company has three programs in clinical development: Del-desiran for myotonic dystrophy type 1 (DM1), Delpacibart braxlosiran for facioscapulohumeral muscular dystrophy (FSHD), and Del-zota for Duchenne muscular dystrophy (DMD). The article also provides detailed company information, including executive leadership, shareholdings, and institutional investor data.
RNA|Avidity Biosciences Inc|Price:11.489|Chg%:-0.421
Avidity Biosciences Inc. (RNA) is trading at $11.489, down 3.53%. Despite recent stock market underperformance, the company shows strong fundamentals, high growth potential, and is considered fairly valued by analysts. Avidity Biosciences is a biopharmaceutical company developing RNA therapeutics called antibody oligonucleotide conjugates (AOCs) with three programs in clinical development.
FDA Clears Atrium Therapeutics' IND Application for Cardiomyopathy Drug
Atrium Therapeutics has received FDA clearance for its Investigational New Drug (IND) application for ATR 1072, a drug designed to treat PRKAG2 syndrome, a rare genetic cardiomyopathy. This clearance allows the company to proceed with its Corventis Phase 1/2 clinical trial. The trial will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ATR 1072, with initial results expected in the second half of 2027.
Atrium Therapeutics awards stock grants to 8 new hires
Atrium Therapeutics (Nasdaq: RNA) granted equity awards to eight new non-executive employees on June 20, 2026, under its 2026 Employment Inducement Incentive Award Plan. The awards include options for 66,000 shares at $12.66 per share and 33,000 Restricted Stock Units (RSUs), with multi-year time-based vesting schedules. These grants, approved under Nasdaq Listing Rule 5635(c)(4), were made outside existing stockholder-approved equity incentive plans to attract and retain new talent.
Avidity Biosciences (RNA) 7th Annual Evercore ISI HealthCONx Healthcare Conference summary
Avidity Biosciences presented a summary of its achievements and strategic updates at the 7th Annual Evercore ISI HealthCONx Healthcare Conference. The company reported consistent positive data across its three neuromuscular programs, expanded into precision cardiology, and is advancing next-generation technology. With $1.6 billion in cash, Avidity Biosciences is progressing towards registrational trials, with key updates expected for its DM1, FSHD, and DMD programs in 2025.
Avidity Biosciences (RNA) Morgan Stanley 23rd Annual Global Healthcare Conference summary
Avidity Biosciences (RNA) presented updates at the Morgan Stanley 23rd Annual Global Healthcare Conference, highlighting three ongoing late-stage clinical trials with BLA filings for Del-zota (DMD) expected by year-end, followed by Del-zota (myotonic dystrophy) and Del-brax (FSHD) in late 2026. The company discussed key data readouts, an optimized dosing strategy for its AOC platform, and the design of the HARBOR trial for myotonic dystrophy, which has regulatory alignment across major regions.
